TOP TEN perturbations for 1097_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1097_s_at
Selected probe(set): 206337_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1097_s_at (206337_at) across 6672 perturbations tested by GENEVESTIGATOR:

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):6.3676634
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):5.9801683
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):5.533106
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

PMA study 7 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):5.4093
Number of Samples:3 / 7
Experimental PMA study 7 (24h)
HepG2 cells exposed to 500nM phorbol-12-myristat-13-acetate [(PMA ortetradecanoyl phorbol acetate (TPA)] in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

CBFA2T3 depletion; IKKb(EE) overexpression study 1 / CBFA2T3 depletion study 1

Relative Expression (log2-ratio):5.3944035
Number of Samples:2 / 2
Experimental CBFA2T3 depletion; IKKb(EE) overexpression study 1
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and pRK5 vector overexpressing constitutively active form of IκB kinase β (IKKb(EE)) along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.
Control CBFA2T3 depletion study 1
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and empty pRK5 vector along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.

Burkitt lymfoma study 4 (MAP2K inhibitor) / Burkitt lymfoma study 4 (control)

Relative Expression (log2-ratio):-5.364197
Number of Samples:3 / 5
Experimental Burkitt lymfoma study 4 (MAP2K inhibitor)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment and isolated after MAP2K inhibition. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.
Control Burkitt lymfoma study 4 (control)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-5.208153
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

CBFA2T3 depletion; IKKb(EE) overexpression study 1 / control transfected Reh cell sample

Relative Expression (log2-ratio):5.076584
Number of Samples:2 / 2
Experimental CBFA2T3 depletion; IKKb(EE) overexpression study 1
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and pRK5 vector overexpressing constitutively active form of IκB kinase β (IKKb(EE)) along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.
Control control transfected Reh cell sample
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing scramled shRNA and empty pRK5 vector along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.

C. pneumoniae study 1 / uninfected monocyte-derived dendritic cell sample

Relative Expression (log2-ratio):4.5636578
Number of Samples:2 / 2
Experimental C. pneumoniae study 1
Monocyte-derived dendritic cells from healthy donors were infected with Chlamydia pneumoniae at a multiplicity of infection of 5 for 72 h.
Control uninfected monocyte-derived dendritic cell sample
Uninfected monocyte-derived dendritic cells from healthy donors.

kidney transplantation study 12 (2 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-4.4094696
Number of Samples:6 / 5
Experimental kidney transplantation study 12 (2 week)
CD4+ T-cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.